6 days Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? Yahoo Finance X
1 week After Eli Lilly’s 7% Slump On Its Guidance Cut, What’s Left To Like? A Lot, Says One Analyst. Investor's Business Daily X
1 week Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today. Yahoo Finance X
1 week Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript) Seeking Alpha X
1 week Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected Yahoo Finance X
1 week Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow Investor's Business Daily X
1 week Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs The Wall Street Journal X
1 week These Stocks Moved the Most Today: Palantir, Nvidia, Eli Lilly, Boeing, KB Home, Signet, Aehr, and More Yahoo Finance X
2 weeks Eli Lilly to buy Scorpion Therapeutics’ cancer therapy for up to $2.5 billion Investing.com X
2 weeks Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 billion Investing.com X
2 weeks Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly MarketWatch X
2 weeks Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound. YouTube X
3 weeks Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential Seeking Alpha X
3 weeks Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know Zacks X
1 month Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength. Yahoo Finance X
1 month Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. Yahoo Finance X
1 month Eli Lilly’s Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? Investor's Business Daily X
1 month Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture YouTube X
1 month Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now Seeking Alpha X
1 month IBD 50’s Hims & Hers Tumbles After FDA Pulls Lilly’s Weight-Loss Drug From Shortage List Investor's Business Daily X
1 month Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook Seeking Alpha X
1 month Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? Investor's Business Daily X
1 month Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly CNBC X
1 month Eli Lilly to test obesity drugs to treat addiction in 2025, CEO says #shorts #weightloss #zepbound YouTube X
1 month The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group Zacks X
2 months Prescription fills for weight loss drugs Zepbound, Wegovy more than doubled in 2024, GoodRx says CNBC X
2 months The Weight-Loss Battle That Could Rattle Eli Lilly’s $100 Billion Market Investor's Business Daily X
Stock Market News